Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has begun dosing in a new triple combination cohort (cohort 12) that includes JNJ-3989 (formerly ARO-HBV) and additional undisclosed agents selected by Janssen Pharmaceuticals, Inc. in its ongoing Phase 1/2 study (AROHBV1001) in patients with chronic hepatitis B virus (HBV). In connection with the start of this new cohort, Arrowhead has earned a $25 million milestone payment from Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen

Pasadena. CA | Posted on April 23rd, 2019

Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead, said: “Both Arrowhead and Janssen share the aim to advance transformational medicines that achieve higher rates of functional cure with a finite treatment duration for patients with chronic hepatitis B viral infection. Beginning this new triple combination cohort in our ongoing AROHBV1001 study has the potential to generate valuable data rapidly.”

AROHBV1001 (NCT03365947) is a Phase 1/2 clinical study evaluating the safety, tolerability, and pharmacokinetic effects of single-ascending doses (SAD) of ARO-HBV in healthy adult volunteers, as well as the safety, tolerability, and pharmacodynamic effects of multiple-ascending doses (MAD) of ARO-HBV in patients with chronic HBV.

Arrowhead entered into a license and collaboration agreement with Janssen in October 2018 to develop and commercialize ARO-HBV. Under the initial terms of the HBV license agreement, Arrowhead was eligible to receive a $50 million milestone payment linked to a Phase 2 study. Arrowhead and Janssen subsequently amended the HBV license agreement to accelerate the payment of $25 million of the $50 million Phase 2 milestone with the initiation of cohort 12 of the AROHBV1001 trial. Arrowhead is eligible to receive the remaining $25 million upon the initiation of a Phase 2 study by Janssen.

Hepatitis B infection is a life-threatening viral infection of the liver, which can cause cirrhosis — scarring of liver tissue — and liver cancer if the infection becomes chronic. The World Health Organization cites that hepatitis B is a global public health problem with 257 million people living with the disease, resulting in 887,000 deaths in 2015.1 While a preventive vaccine is available, cure rates for those infected remain low and most patients will endure lifelong therapy.

1 World Health Organization (WHO). Hepatitis B. July 2017. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanometrics to Announce Second Quarter Financial Results on July 30, 2019 July 17th, 2019

Breakthrough material could lead to cheaper, more widespread solar panels and electronics July 16th, 2019

Caught in the act: Images capture molecular motions in real time July 15th, 2019

NUS ‘smart’ textiles boost connectivity between wearable sensors by 1,000 times: Metamaterials are incorporated into conventional clothing to dramatically improve signal strength between electronic devices, allowing for new applications July 15th, 2019

Possible Futures

Breakthrough material could lead to cheaper, more widespread solar panels and electronics July 16th, 2019

Caught in the act: Images capture molecular motions in real time July 15th, 2019

Dresden physicists use nanostructures to free photons for highly efficient white OLEDs: Trapped light particles July 12th, 2019

Strange warping geometry helps to push scientific boundaries July 12th, 2019

Nanomedicine

An 'EpiPen' for spinal cord injuries July 12th, 2019

Nanotechnology delivers hepatitis B vaccine: X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response. The material can give rise to a polyvaccine against six diseases July 12th, 2019

Sheaths drive powerful new artificial muscles July 11th, 2019

Nanotechnology pioneer Chad Mirkin wins Kabiller Prize in Nanoscience and Nanomedicine: Molly Stevens of Imperial College London receives Kabiller Young Investigator Award July 11th, 2019

Announcements

Nanometrics to Announce Second Quarter Financial Results on July 30, 2019 July 17th, 2019

Breakthrough material could lead to cheaper, more widespread solar panels and electronics July 16th, 2019

Caught in the act: Images capture molecular motions in real time July 15th, 2019

NUS ‘smart’ textiles boost connectivity between wearable sensors by 1,000 times: Metamaterials are incorporated into conventional clothing to dramatically improve signal strength between electronic devices, allowing for new applications July 15th, 2019

Nanobiotechnology

An 'EpiPen' for spinal cord injuries July 12th, 2019

Nanotechnology delivers hepatitis B vaccine: X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response. The material can give rise to a polyvaccine against six diseases July 12th, 2019

Nanotechnology pioneer Chad Mirkin wins Kabiller Prize in Nanoscience and Nanomedicine: Molly Stevens of Imperial College London receives Kabiller Young Investigator Award July 11th, 2019

Imprinted spheres fight breast cancer: Inhibition of HER2 on tumor cells by molecularly imprinted nanoparticles July 9th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project